Acevector, Snapdeal's parent company, entered its final day of public subscription today, September 29, 2026. The ₹420.00 crore IPO is priced at ₹30 to ₹32 per share, and as of 10:15 AM on Day 3, the issue had been subscribed 1.23 times.
The basis of allotment is expected to be finalised on September 30, 2026, while the shares are tentatively scheduled to list on the BSE and NSE on October 5, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
25 September 2026 |
|
Subscription Closing Date |
29 September 2026 |
|
Basis of Allotment Date |
30 September 2026 |
|
Refund Initiation Date |
1 October 2026 |
|
Credit of Shares |
1 October 2026 |
|
Listing on BSE and NSE |
5 October 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[September 29, 2026, 10:15 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
1.03x |
|
Non-Institutional Investors (NIIs) |
1.35x |
|
Retail Individual Investors (RIIs) |
1.62x |
|
Total |
1.23x |
The company intends to utilise the net proceeds from the fresh issue towards:
Incorporated in 2007, AceVector Limited operates a digital commerce ecosystem through its subsidiaries, providing AI- and technology-driven solutions across e-commerce, SaaS and consumer brands. Its portfolio includes Snapdeal, a value-focused online marketplace, and Uniware, Convertway and Shipway, which offer software solutions for e-commerce businesses.
The company also owns Stellaro Brands, a portfolio of value-oriented consumer brands. In FY2026, Snapdeal served customers across 18,972 PIN codes in India, with a focus on Tier 2 and smaller cities.
|
Particulars |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
FY24 (in ₹ crore) |
|
Revenue from operations |
510.38 |
395.02 |
379.76 |
|
EBITDA |
(15.94) |
(39.16) |
(26.52) |
|
Loss for the year |
(45.51) |
(126.31) |
(51.30) |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here